Edgar Filing: PAPPAJOHN JOHN - Form 4/A

PAPPAJOH Form 4/A August 18, 2											
FORM	14 UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									
Check th if no lon subject t Section Form 4 o Form 5 obligation may con <i>See</i> Instr 1(b). (Print or Type	ger o 16. or Filed pur ons tinue. vuction	rsuant to Sec (a) of the Pub	EHANGES IN SECUR tion 16(a) of th blic Utility Hold the Investment	Expires: January 31 2009 Estimated average burden hours per response 0.9							
PAPPAJOHN JOHN Symbol			mbol	er Name and Ticker or Trading CER GENETICS, INC [CGIX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) 201 ROUT FLOOR	Date of Earliest Tr Ionth/Day/Year) 8/17/2017	of Earliest Transaction /Day/Year)X_ Director					X 10% Owner e title Other (specify below)				
RUTHERF	(Street) ORD, NJ 07070	Fil	If Amendment, Da ed(Month/Day/Year 8/18/2017	-			6. Individual or Jo Applicable Line) _X_ Form filed by O Form filed by M Person	one Reporting Pe	rson		
(City)	(State)	(Zip)	Table I - Non-D	Derivative S	Securi	ities Acq	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Data (Month/Day/Year)	ransaction Date 2A. Deemed nth/Day/Year) Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired Transactior(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Price			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Ownership		
Common Stock, par value \$0.0001 per share	08/17/2017		Р	66,185	A	\$ 3.235 (1)	2,608,704	D			
Common Stock, par value \$0.0001 per share	08/18/2017 <u>(2)</u>		Р	20,000	A	\$ 3.278 (3)	2,628,704	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: PAPPAJOHN JOHN - Form 4/A

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	ate	7. Titl Amou Under Securi (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
PAPPAJOHN JOHN 201 ROUTE 17 NORTH 2ND FLOOR RUTHERFORD, NJ 07070	Х	Х					
Signatures /s/ John Pappajohn by John A.	S		08/18/2017				
Attorney-in-fact							

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$3.15 to \$3.30, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

- (2) The original Form 4, filed on August 18, 2017 is amended to correctly reflect the transaction date. No other changes have been made to the original Form 4.
- (3) 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$3.25 to \$3.30, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at

Edgar Filing: PAPPAJOHN JOHN - Form 4/A

each separate price within the ranges set forth in footnote (2) to this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.